Inventiva (IVEVF) Cash from Financing Activities (2019 - 2022)
Inventiva (IVEVF) posted Cash from Financing Activities of $14.2 million for Q4 2022, down 2.22% on a QoQ basis from $14.6 million in Q3 2022, and up 40038.88% year-over-year from N/an in Q4 2021.
Analysis
Inventiva (IVEVF) Cash from Financing Activities (2019 - 2022) Analysis & Trends
Inventiva has reported Cash from Financing Activities for 4 years, with the latest figure at $14.2 million in Q4 2022.
- On a quarterly basis, Cash from Financing Activities rose 40038.88% year-over-year to $14.2 million in Q4 2022; TTM through Dec 2022 was $24.6 million, a 16.38% decrease from a year earlier, with the FY2025 full-year figure at $280.9 million, up 80.53% from the prior year.
- Cash from Financing Activities was $14.2 million for Q4 2022 at Inventiva, down from $14.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $29.3 million in Q4 2020, with the low at -$4.2 million in Q2 2021.
- Average Cash from Financing Activities over 4 years is $9.5 million, with a median of $11.0 million recorded in 2020.
- The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities slumped 138.5% in 2021, then jumped 40038.88% in 2022.
- Over 4 years, Cash from Financing Activities stood at -$132826.5 in 2019, then soared by 22187.97% to $29.3 million in 2020, then plunged by 99.88% to $35463.1 in 2021, then surged by 40038.88% to $14.2 million in 2022.
- The last three Cash from Financing Activities figures came in at $14.2 million (Q4 2022), $14.6 million (Q3 2022), and $35463.1 (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | -3.66 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.10 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | 2.42 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 65.46 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 122.40 Mn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 14.23 Mn |
| Sep 22, 2022 | 14.56 Mn |
| Dec 31, 2021 | 35,463.10 |
| Jun 30, 2021 | -4.23 Mn |
| Mar 31, 2021 | 4.27 Mn |
| Dec 31, 2020 | 29.34 Mn |
| Jun 30, 2020 | 10.99 Mn |
| Mar 31, 2020 | 16.15 Mn |
| Dec 31, 2019 | -132,826.52 |